Document is current
Any future updates will be listed below
-
Authors
Nikolaienko, Oleksii https://orcid.org/0000-0002-5910-4934
Eikesdal, Hans P.
Ognedal, Elisabet https://orcid.org/0000-0003-4775-0661
Gilje, Bjørnar https://orcid.org/0000-0002-6777-4081
Lundgren, Steinar
Blix, Egil S.
Espelid, Helge
Geisler, Jürgen
Geisler, Stephanie
Janssen, Emiel A. M. https://orcid.org/0000-0002-7760-5396
Yndestad, Synnøve https://orcid.org/0000-0001-7835-3031
Minsaas, Laura https://orcid.org/0009-0008-9775-3880
Leirvaag, Beryl
Lillestøl, Reidun https://orcid.org/0009-0009-7453-1027
Knappskog, Stian https://orcid.org/0000-0002-4153-1655
Lønning, Per E. https://orcid.org/0000-0002-8890-6303
-
Funding
Funding for this research was provided by:
Stiftelsen Kristian Gerhard Jebsen
Helse Vest
Norges Forskningsråd
Kreftforeningen
University of Bergen
- License Information
-
More Information
Article History
Received: 9 June 2023
Accepted: 16 November 2023
First Online: 6 December 2023
Declarations
:
: All participants in the clinical studies provided written informed consent, and the current study is covered by each consent. All studies were approved by the Regional Ethics Committee (reference numbers: 273/96–82.96, 06/3077 and 2015/1493). Each part of the study conformed to the Helsinki Declaration of research on humans.
: Not applicable.
: Research Funding (<i>to Institution</i>): Astellas Oncology (BG), AstraZeneca (HPE, BG, SK, PEL, ESB), Celgene (BG), Novartis (HPE, PEL), Pfizer (HPE, SK, BG, PEL).Honoraria: Amgen (HPE), AstraZeneca (HPE, BG, TA, EAMJ, SK, PEL), Abbvie (PEL), Bristol-Myers-Squibb (HPE, JG), Dagens Medisin (HPE, PEL), Eli Lilly (JG), HAI Interaktiv AS (HPE), MSD (JG), Novartis (HPE, JG, SK), Pfizer (HPE, EAJ, SK), Pierre Fabre (HPE, JG, SK, PEL), Roche (HPE, BG, TA, PEL).Consulting or Advisory Role: Aptitude Health (HPE), Astellas Oncology (BG), AstraZeneca (ESB, JG, PEL), Daiichi Sankyo (ESB, HPE), Eli Lilly (ESB, HPE, JG), Gilead (ESB), Laboratorios Farmaceuticos Rovi (PEL), MSD (ESB, HPE, JG), Novartis (ESB, HPE, JG), Pfizer (HPE), Pierre Fabre (HPE), Roche (HPE, BG).Expert Testimony: Pfizer (HPE).Travel, Accomodations, Expenses: AstraZeneca (HPE), Pierre Fabre (HPE, BG, PEL), Roche (BG).Speakers’ Bureau: Akademikonferens (PEL), Aptitude Health (PEL), AstraZeneca (JG), Bristol-Myers-Squibb (JG), MSD (JG), Novartis (JG), Pfizer (JG), Pierre Fabre (JG).Patents, Royalties, Other Intellectual Property: Patent EP2389450 A1 (SK), Patent WO 2012/010661 (SK), Cytovation (PEL).All remaining authors have declared no conflicts of interest.
